Stallergenes

Results: 25



#Item
1Corporate Presentation January 2016 A world-class specialty biopharma business

Corporate Presentation January 2016 A world-class specialty biopharma business

Add to Reading List

Source URL: www.circassia.com

Language: English - Date: 2016-01-11 11:48:32
2ORALAIR® is a registered trademark of Stallergenes SA and marketed by Stallergenes Canada Inc. PRODUCT MONOGRAPH  Pr

ORALAIR® is a registered trademark of Stallergenes SA and marketed by Stallergenes Canada Inc. PRODUCT MONOGRAPH Pr

Add to Reading List

Source URL: www.stallergenes.ca

Language: English - Date: 2015-06-12 13:15:16
    3Microsoft Word - ActoGeniX-Stallergenes Press Release ENGdef

    Microsoft Word - ActoGeniX-Stallergenes Press Release ENGdef

    Add to Reading List

    Source URL: www.actogenix.com

    Language: English - Date: 2014-11-20 05:36:21
      4Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol

      Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol

      Add to Reading List

      Source URL: www.ctajournal.com

      Language: English
      5Clinical and Molecular Allergy.eps

      Clinical and Molecular Allergy.eps

      Add to Reading List

      Source URL: www.clinicalmolecularallergy.com

      Language: English
      6leaflet_acariens_7244V3.pdf

      leaflet_acariens_7244V3.pdf

      Add to Reading List

      Source URL: www.stallergenes.fr

      Language: French - Date: 2014-10-21 05:00:26
        7Stallergenes worldwide HEADQUARTERS STALLERGENES 6, rue Alexis de Tocqueville CSAntony Cedex Tel.: +00

        Stallergenes worldwide HEADQUARTERS STALLERGENES 6, rue Alexis de Tocqueville CSAntony Cedex Tel.: +00

        Add to Reading List

        Source URL: www.stallergenes.fr

        Language: English - Date: 2015-02-26 11:16:17
        8leaflet_arbres_7210V5.pdf

        leaflet_arbres_7210V5.pdf

        Add to Reading List

        Source URL: www.stallergenes.fr

        Language: French - Date: 2014-10-21 05:00:27
          9Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of patients with mild asthma

          Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of patients with mild asthma

          Add to Reading List

          Source URL: www.worldallergy.org

          Language: English - Date: 2015-01-12 13:25:07
          1019 May 2014 EMA[removed]Patient Health Protection Organisation funding sources NAME OF ORGANISATION: European Federation of Allergy and Airways Diseases Patients’ Associations EFA

          19 May 2014 EMA[removed]Patient Health Protection Organisation funding sources NAME OF ORGANISATION: European Federation of Allergy and Airways Diseases Patients’ Associations EFA

          Add to Reading List

          Source URL: www.efanet.org

          Language: English - Date: 2014-10-06 07:14:41